

DCAT
TOP ↑
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*



DCAT
AFTER THE SHOW A Member Company Networking Event

BARCELONA 2016

WEDNESDAY OCTOBER 5TH • 6:00 PM – 8:30 PM • CASA LLOTJA DE MAR

1. [Teva Gets FTC OK for \\$40.5 Billion Acquisition of Allergan's Generics Business](#)

Teva Pharmaceutical Industries has received approval from the US Federal Trade Commission (FTC) for its proposed \$40.5 billion acquisition of the generics business of Allergan. In giving its okay, the FTC is requiring Teva to divest nearly 80 products. The deal is expected to close next week. [Read More](#)

2. [Lilly's Lechleiter To Retire as Chairman, President and CEO; Successor Named](#)

John C. Lechleiter, chairman, president, and chief executive officer (CEO) of Eli Lilly and Company, will retire as president and CEO, effective December 31, 2016. He will continue on Lilly's board of directors until May 31, 2017, serving as non-executive chairman, at which time he will leave the board. Lilly's board of directors unanimously elected David A. Ricks, currently senior vice president and president, Lilly Bio-Medicines, to assume the role of president and CEO and to join the board on January 1, 2017, and to become chairman of the board on June 1, 2017. [Read More](#)

3. [FTC Clears Mylan's \\$7.2 Billion Acquisition of Meda](#)

The US Federal Trade Commission (FTC) has cleared Mylan's proposed \$7.2 billion acquisition of Meda Aktiebolag, a Swedish pharmaceutical company, subject to Mylan's divestiture of certain products. The FTC clearance represents the final regulatory clearance required to complete Mylan's offer, and Mylan has now received all antitrust regulatory clearances required to acquire Meda. [Read More](#)

4. [GSK To Invest Approximately \\$360 Million at Three UK Manufacturing Sites](#)

GlaxoSmithKline plans to invest £275 million (\$362 million) at three of its manufacturing sites in the UK to boost production and support delivery of respiratory and biological medicines. The vast majority of these products will be for export to global markets. [Read More](#)

5. [Monsanto Rejects Bayer's \\$65 Billion Acquisition Proposal](#)

Monsanto, the agrochemical and seed company, has rejected Bayer's increased all-cash offer to acquire the company for \$125 per share or approximately \$65 billion. Bayer had earlier made a \$62 billion bid for Monsanto, its first large-scale acquisition effort since becoming a pure-play life sciences company focused on pharmaceuticals, crop science, and consumer healthcare. [Read More](#)

6. [Valeant Receives FDA Complete Response Letter for Eye-Care Drug Over Manufacturing Issues](#)

Valeant Pharmaceuticals International has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for its new drug application for latanoprostene bunod ophthalmic solution, 0.024%, a single-agent eye drop for open angle glaucoma or ocular

hypertension. The FDA raised concerns about a cGMP inspection at Bausch + Lomb's manufacturing facility in Tampa, Florida where the agency identified some deficiencies. [Read More](#)

7. [Mylan Launches Generic of AstraZeneca's Crestor](#)

Mylan has launched rosuvastatin calcium tablets, 5 mg, 10 mg, 20 mg, and 40 mg, a generic version of AstraZeneca's anti-cholesterol drug, Crestor, in the US following final FDA approval. The drug had US sales of approximately \$6.7 billion for the 12 months ending May 31, 2016, according to IMS Health, and as reported by Mylan. [Read More](#)

8. [FDA Announces GDUFA User Fees for FY 2017](#)

The FDA has announced the rates for abbreviated new drug applications (ANDAs), prior approval supplements to an approved ANDA, drug master file, generic drug active pharmaceutical ingredient facilities, and finished dosage form facilities user fees related to the Generic Drug User Fee Program for fiscal year 2017. [Read More](#)

9. [China's Fosun Pharmaceutical To Acquire India's Gland Pharma for Nearly \\$1.3 Billion](#)

Fosun Pharmaceutical, a Shanghai-based healthcare company, has agreed to acquire an approximate 86% stake in Gland Pharma, an Indian pure-play generic injectable pharmaceutical products company, for up to \$1.26 billion. [Read More](#)

10. [EMA Suspends Certain Drugs Using Data from Bangalore, India-Based CRO](#)

The European Medicines Agency has recommended suspending a number of nationally approved medicines for which bioequivalence studies were conducted at Semler Research Center Private Ltd., a contract research organization based in Bangalore, India. The agency has also recommended that medicines currently being evaluated for authorization and which rely only on bioequivalence studies from this site should not be authorized until bioequivalence is demonstrated using alternative data. Bioequivalence studies usually form the basis for approval of generic medicines. [Read More](#)

****Upcoming DCAT Event****

[DCAT After the Show](#)

Don't miss DCAT's inaugural networking event following CPhI Worldwide in Barcelona on Wednesday, October 5th from 6:00 PM to 8:30 PM at the beautiful Casa Llotja de Mar. Located just steps away from the Gothic Quarter and Port of Barcelona, this event offers the perfect opportunity to utilize that time between the tradeshow and your late-night dinner plans to catch up with colleagues and establish valuable industry connections.

Registration for this event is now open. The reception is \$79.00 USD per person, and includes food and beverage, and transportation from the show to Casa Llotja de Mar, compliments of ACIC Fine Chemicals, Inc. Further event information and available branding opportunities may be found [here](#).

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

[About Top Industry News](#)

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org